To date, randomized controlled and prospective population-based trials [32–35] that have assessed the impact of n-3 PUFAs on T2D and insulin sensitivity have provided inconsistent results regarding their effectiveness in preventing or treating T2D. The gene discussed is INS; the disease is type 2 diabetes mellitus.